65,437 trials
Pneumonia
Primary: Number of Participants With Pneumonia — 21; 2 participants — p=<0.001
Waldenstrom Macroglobulinaemia
Primary: Number of Participants With Overall Response (OR) for Cycle 1 (Including the Redosing Cycle), as Assessed by the Investigator — 7; 15 participants
Basal Cell Carcinoma
Primary: Objective Response (OR) Determined by the Independent Review Facility — 30.3; 42.9 Percentage of participants — p=0.0011
Deep Vein Thrombosis · Pulmonary Embolism
Primary: Major Bleeding Complication — 0; 3 participants
Alzheimer Disease
Primary: Whole Body Radiation Dosimetry — 0.0186; 0.0136; 0.01; 0.00624 mSv/MBq
Primary Dyslipidemia · Mixed Dyslipidemia
Primary: Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12 — -34.8; -22.7 percent
Aspergillosis
Primary: All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive Aspergillosis — 26; 39 participants — p=0.0434
HIV Infections
Primary: Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline — 4.854; 4.861; 4.840 log10 copies/milliliter(log10 copies/mL)
Acute Hypoxemic Respiratory Failure
Primary: Duration of Mechanical Ventilation Through 14 Days — 4.0; 4.5 days
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12 — 24.90; 24.86; 23.79; 23.78 Millimeters of Mercury (mmHg)
Ovarian Cancer
Primary: Progression-free Survival (PFS) — 7.5; 5.8 Months
Periodontitis
Primary: HbA1c Levels in Blood — 11.42; 10.81 percentage of HbA1c levels in blood — p=0.05
Biliary Tract Surgical Procedures · Pancreaticoduodenectomy · Esophagectomy
Primary: Post-operative Blood Loss — 394.3; 494.3 milliliter (mL) — p=0.460
Venous Thrombosis
Primary: Emax (Maximum Effect) on Prothrombin Time (PT) (Coagulation Test) — 4.393; 1.884; 1.573 ratio — p=<0.0001
Restless Legs Syndrome
Primary: Change in Restless Legs Syndrome Rating Scale — -5.0; -1.0; -2.7; -5.0 RLS Rating Score